JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com - NovaBay Pharmaceuticals reported on Monday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
NovaBay Pharmaceuticals announced earnings per share of $-0.1000 on revenue of $3.83M. Analysts polled by Investing.com EPS of $-0.0300 on revenue of $3.75M.
NovaBay Pharmaceuticals 's are down 30% and is trading at $0.0898 , still down 84.78% from its 52 week high of $0.59 set on Monday, December 13, 2021.
NovaBay Pharmaceuticals follows other major Healthcare sector earnings this month
NovaBay Pharmaceuticals's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar